These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9635571)

  • 1. Beta-catenin mutations in human prostate cancer.
    Voeller HJ; Truica CI; Gelmann EP
    Cancer Res; 1998 Jun; 58(12):2520-3. PubMed ID: 9635571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
    Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
    Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
    Garcia-Rostan G; Tallini G; Herrero A; D'Aquila TG; Carcangiu ML; Rimm DL
    Cancer Res; 1999 Apr; 59(8):1811-5. PubMed ID: 10213482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.
    Shigemitsu K; Sekido Y; Usami N; Mori S; Sato M; Horio Y; Hasegawa Y; Bader SA; Gazdar AF; Minna JD; Hida T; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Shimokata K
    Oncogene; 2001 Jul; 20(31):4249-57. PubMed ID: 11464291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway.
    Mirabelli-Primdahl L; Gryfe R; Kim H; Millar A; Luceri C; Dale D; Holowaty E; Bapat B; Gallinger S; Redston M
    Cancer Res; 1999 Jul; 59(14):3346-51. PubMed ID: 10416591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-catenin mutation in carcinoma of the uterine endometrium.
    Fukuchi T; Sakamoto M; Tsuda H; Maruyama K; Nozawa S; Hirohashi S
    Cancer Res; 1998 Aug; 58(16):3526-8. PubMed ID: 9721853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
    Wu R; Zhai Y; Fearon ER; Cho KR
    Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence for involvement of beta-catenin and APC in urothelial carcinomas.
    Stoehr R; Krieg RC; Knuechel R; Hofstaedter F; Pilarsky C; Zaak D; Schmitt R; Hartmann A
    Int J Oncol; 2002 May; 20(5):905-11. PubMed ID: 11956582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutation analysis of the beta-catenin gene in epithelial carcinomas of the ovaries].
    Tanyi J; Páy A; Rigó J; Nagy B; Papp Z
    Orv Hetil; 2000 May; 141(21):1115-9. PubMed ID: 10876313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare activation of the TCF/beta-catenin pathway in ovarian cancer.
    Furlong MT; Morin PJ
    Gynecol Oncol; 2000 Apr; 77(1):97-104. PubMed ID: 10739697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of beta-catenin by calpain in prostate and mammary tumor cells.
    Rios-Doria J; Kuefer R; Ethier SP; Day ML
    Cancer Res; 2004 Oct; 64(20):7237-40. PubMed ID: 15492240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3.
    Miyoshi Y; Iwao K; Nagasawa Y; Aihara T; Sasaki Y; Imaoka S; Murata M; Shimano T; Nakamura Y
    Cancer Res; 1998 Jun; 58(12):2524-7. PubMed ID: 9635572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
    Shiina H; Igawa M; Breault J; Ribeiro-Filho L; Pookot D; Urakami S; Terashima M; Deguchi M; Yamanaka M; Shirai M; Kaneuchi M; Kane CJ; Dahiya R
    Clin Cancer Res; 2003 Jun; 9(6):2121-32. PubMed ID: 12796377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.
    Shiina H; Igawa M; Urakami S; Shigeno K; Yoneda T; Terashima M; Deguchi M; Ribeiro-Filho L; Dahiya R
    Cancer Res; 2001 Oct; 61(19):7101-9. PubMed ID: 11585741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common human skin tumour is caused by activating mutations in beta-catenin.
    Chan EF; Gat U; McNiff JM; Fuchs E
    Nat Genet; 1999 Apr; 21(4):410-3. PubMed ID: 10192393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors.
    Kitaeva MN; Grogan L; Williams JP; Dimond E; Nakahara K; Hausner P; DeNobile JW; Soballe PW; Kirsch IR
    Cancer Res; 1997 Oct; 57(20):4478-81. PubMed ID: 9377556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer.
    Park WS; Oh RR; Park JY; Lee SH; Shin MS; Kim YS; Kim SY; Lee HK; Kim PJ; Oh ST; Yoo NJ; Lee JY
    Cancer Res; 1999 Sep; 59(17):4257-60. PubMed ID: 10485468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.
    de la Taille A; Rubin MA; Chen MW; Vacherot F; de Medina SG; Burchardt M; Buttyan R; Chopin D
    Clin Cancer Res; 2003 May; 9(5):1801-7. PubMed ID: 12738737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.